Abstract: Objective To investigate the clinical effect of SGLT2 inhibitor in the treatment of type 2 diabetes mellitus complicated with heart failure. Methods A total of 168 patients with type 2 diabetes and heart failure who were treated in First People's Hospital of Xinmi were selected, and randomly divided into control group and study group with 84 cases in each group. Both groups were given conventional heart failure drug treatment, and the study group was given SGLT2 inhibitor therapy on this basis, and both groups were given continuous treatment for 6 months. Before and after treatment, the blood glucose and serum ST2 and NT-proBNP levels in the two groups were detected, and the cardiac function indexes were monitored, and the incidence of adverse events during treatment and follow-up was compared between the two groups. Results After treatment, the levels of blood glucose FBG, 2h PG and HbAlc, the levels of ST2 and NT-proBNP in the two groups were significantly decreased compared with those before treatment, and compared with the control group, the study group had a more significant decrease (P<0.05). After treatment, the levels of LVEF, SV and 6MWD in the two groups were significantly higher than those before treatment, and the increase in the study group was more significant than that in the control group (P<0.05). Conclusion SGLT2 inhibitors in the treatment of type 2 diabetes mellitus complicated with heart failure can effectively reduce blood glucose and serum ST2 and NT-proBNP levels, and improve cardiac function in patients.

Key words: type 2 diabetes, heart failure, SGLT2 inhibitor, ST2 level, NT-proBNP level

摘要： 目的 探讨SGLT2抑制剂治疗2型糖尿病合并心力衰竭的临床效果。方法 选取2019年5月~2021年10月于新密市第一人民医院就诊的2型糖尿病合并心力衰竭患者168例,随机分为对照组和研究组,每组84例。2组均给予常规心衰药物治疗,研究组在此基础上给予SGLT2抑制剂治疗,2组均连续治疗6个月。治疗前后检测2组血糖及血清ST2、NT-proBNP水平,并监测心脏功能指标。结果 治疗后2组患者空腹血糖（FBG）、餐后2h血糖（2h PG）、糖化血红蛋白（HbAlc）水平、血清ST2、NT-proBNP水平与治疗前比较均有明显下降,且与研究组较对照组有更为明显的降低（P<0.05）;治疗后2组患者LVEDD水平与治疗前比较均有明显降低,且研究组较对照组有更为明显的降低（P<0.05）;治疗后2组患者LVEF、SV、6MWD水平与治疗前比较均有更为明显的升高,且研究组较对照组升高更为明显（P<0.05）。结论 SGLT2抑制剂治疗2型糖尿病合并心力衰竭可有效降低患者血糖及血清ST2、NT-proBNP水平,改善患者心脏功能。

关键词: 2型糖尿病, 心力衰竭, SGLT2抑制剂, ST2水平, NT-proBNP水平